{"id":26620,"date":"2026-07-29T16:01:52","date_gmt":"2026-07-29T10:31:52","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=26620"},"modified":"2026-07-29T18:08:32","modified_gmt":"2026-07-29T12:38:32","slug":"kras-inhibitors-beyond-g12c","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c","title":{"rendered":"Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a7e6fef4fe4a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a7e6fef4fe4a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Epidemiological_Insights_into_Geographic_Distribution_of_KRAS_Mutations\" >Epidemiological Insights into Geographic Distribution of KRAS Mutations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#The_Therapeutic_Landscape_of_KRAS_Inhibitors_Progress_and_Promise\" >The Therapeutic Landscape of KRAS Inhibitors: Progress and Promise<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Expanding_Opportunities_in_KRAS-mutated_Colorectal_Cancer_CRC\" >Expanding Opportunities in KRAS-mutated Colorectal Cancer (CRC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Next-generation_KRAS_Inhibitors_to_Reshape_the_Current_Therapeutic_Landscape\" >Next-generation KRAS Inhibitors to Reshape the Current Therapeutic Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Pipeline_Setbacks_Reshaping_the_KRAS_Therapeutic_Landscape\" >Pipeline Setbacks Reshaping the KRAS Therapeutic Landscape&nbsp;<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Future_Outlook_of_the_KRAS_Inhibitors_Market\" >Future Outlook of the KRAS Inhibitors Market&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Conclusion_A_Glimpse_into_the_Future\" >Conclusion: A Glimpse into the Future<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\/#Frequently_Asked_Questions\" >Frequently Asked Questions<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The KRAS G12C mutation obstructs the binding of GAP to KRAS, preventing GTP hydrolysis and keeping G12C-mutant KRAS continuously active. This sustained activation triggers the MAPK and PI3K signaling pathways, fueling the formation of tumors. Drugs like sotorasib and adagrasib directly target KRAS G12C by forming a bond with cysteine 12 in the KRAS-G12C protein\u2019s switch-II pocket. This action locks KRAS in an inactive state, halting cell proliferation. While inhibiting KRAS G12C proves effective against certain lung cancers, it doesn\u2019t impact PI3K signaling. This suggests that alternative pathways unrelated to KRAS-G12C might activate PI3K, contributing to resistance against G12C inhibitors and prompting the development of new therapies. G12C stands as the primary focus in KRAS targeting, yet newer studies reveal emerging targets like G12D, although their treatment paths are less established. Some companies are exploring PAN-KRAS inhibition as a novel treatment method. For instance, Onvansertib, currently in a Phase II trial for metastatic colorectal cancer treatment, aims to address all KRAS mutations by activating PLK1, which triggers RAS downstream pathways.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-epidemiological-insights-into-geographic-distribution-of-kras-mutations\"><span class=\"ez-toc-section\" id=\"Epidemiological_Insights_into_Geographic_Distribution_of_KRAS_Mutations\"><\/span><strong>Epidemiological Insights into Geographic Distribution of KRAS Mutations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The identification of KRAS mutations dates back to the 1980s, and it has since been recognized as a prevalent mutation in various cancers such as lung cancer, colorectal cancer, and pancreatic cancer. Among these, the G12C variant is the most widespread in non-small cell lung cancer (NSCLC) across the United States, Europe, and Japan, occurring in approximately <strong>35\u201340%<\/strong> of <a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-inhibitors-market\">KRAS-mutated NSCLC patients<\/a> in 2025, as per DelveInsight analysis. Immunotherapy stands as the standard of care for individuals with KRAS-mutant NSCLC, especially those with G12C variations, as there are currently no authorized treatments specifically targeting this variant.<\/p>\n\n\n\n<p>In colorectal cancers, around <strong>40%<\/strong> exhibit KRAS mutations, with G12D being the predominant variant found in about <strong>25\u201335% <\/strong>of individuals with KRAS mutations. Despite G12D being the most common variant, the majority of KRAS therapies for colorectal cancer focus on G12C, despite its lower prevalence in this cancer type. Ongoing developments include limited treatments for G12D and PAN-KRAS variants.<\/p>\n\n\n\n<p>Pancreatic cancer, where KRAS mutations are present in <strong>60\u201390%<\/strong> of patients, sees G12D as the most frequent KRAS variant, occurring in approximately <strong>40\u201350%<\/strong> of KRAS-mutated patients. However, the development of effective \u201csystemic\u201d and \u201cbiomarker-specific\u201d therapies for pancreatic cancer patients remains a substantial unmet need. Recognizing this, several key players in the pharmaceutical and biotech industries are increasingly exploring the potential of targeting KRAS mutations in pancreatic cancer, seeing this relatively unexplored segment as a promising market opportunity for cancer treatment.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"365\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Patient-Pool-Analysis-1024x365.webp\" alt=\"KRAS-Inhibitors-Patient-Pool-Analysis\" class=\"wp-image-35878\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Patient-Pool-Analysis-1024x365.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Patient-Pool-Analysis-300x107.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Patient-Pool-Analysis-150x53.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Patient-Pool-Analysis-768x274.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Patient-Pool-Analysis-1536x547.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Patient-Pool-Analysis.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-therapeutic-landscape-of-kras-inhibitors-progress-and-promise\"><span class=\"ez-toc-section\" id=\"The_Therapeutic_Landscape_of_KRAS_Inhibitors_Progress_and_Promise\"><\/span><strong>The Therapeutic Landscape of KRAS Inhibitors: Progress and Promise<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>KRAS-targeted therapy has rapidly evolved from a long-standing scientific challenge into one of oncology&#8217;s most competitive therapeutic areas. A major breakthrough came with the approval of <strong>Amgen\u2019s sotorasib (LUMAKRAS)<\/strong>, the first approved targeted <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\">treatment for NSCLC patients<\/a> with the KRAS G12C mutation in 2021, followed by <strong>Bristol Myers Squibb&#8217;s adagrasib (KRAZATI)<\/strong> in 2022. Both therapies received accelerated approvals based on their ability to deliver clinically meaningful responses in KRAS G12C-mutated NSCLC, establishing KRAS as a druggable oncogenic target after decades of failed attempts. While both therapies have demonstrated comparable efficacy, they differ in their clinical profiles. Adagrasib demonstrates the ability to penetrate the central nervous system, making it a valuable treatment option for patients with brain metastases, which develop in <strong>approximately 40% <\/strong>of patients with KRAS G12C-mutated NSCLC during the course of their disease. In contrast, sotorasib is generally associated with a more favorable safety profile and longer duration of response. However, adagrasib has been associated with QTc interval prolongation and gastrointestinal toxicities, necessitating careful clinical monitoring during treatment.<\/p>\n\n\n\n<p>In the United States, Mirati\u2019s drug adagrasib is priced at <strong>USD 19,750<\/strong> for a 30-day supply, whereas sotorasib has a lower list price of <strong>USD 17,900<\/strong> per month. Sotorasib, with an estimated list price of GBP 6,907 for a 30-day supply of 240 tablets (each containing 120 mg, excluding VAT and business submission), has a commercial arrangement in place (including a managed access agreement and a commercial access agreement). Adagrasib has not yet received licensing in Europe. Sotorasib 120 mg tablets are priced at approximately JPY 4,204 per tablet. Comparatively, current pricing indicates that in Japan and the UK, the prices are approximately <strong>60% and 50%<\/strong> lower than those in the US. As competition intensifies, future pricing and reimbursement strategies are expected to evolve alongside the arrival of newer KRAS inhibitors.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"316\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Timeline-of-KRAS-Inhibitors-1024x316.webp\" alt=\"Timeline-of-KRAS-Inhibitors\" class=\"wp-image-35879\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Timeline-of-KRAS-Inhibitors-1024x316.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Timeline-of-KRAS-Inhibitors-300x93.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Timeline-of-KRAS-Inhibitors-150x46.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Timeline-of-KRAS-Inhibitors-768x237.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Timeline-of-KRAS-Inhibitors-1536x474.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Timeline-of-KRAS-Inhibitors.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-expanding-opportunities-in-kras-mutated-colorectal-cancer-crc\"><span class=\"ez-toc-section\" id=\"Expanding_Opportunities_in_KRAS-mutated_Colorectal_Cancer_CRC\"><\/span><strong>Expanding Opportunities in KRAS-mutated Colorectal Cancer (CRC)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Over 40% of <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-colorectal-cancer-market\">individuals with metastatic CRC<\/a> exhibit a KRAS mutation, rendering them intrinsically resistant to anti-EGFR monoclonal antibody monotherapy and representing a major unmet need in precision oncology. While <strong>KRAS G12C<\/strong> accounts for only approximately <strong>3\u20134%<\/strong> of mCRC cases, it has become the first KRAS subtype to benefit from targeted therapies. <strong>Amgen&#8217;s sotorasib (LUMAKRAS)<\/strong>, in combination with panitumumab, became the first KRAS G12C-targeted regimen approved for previously treated mCRC based on the Phase III CodeBreaK 300 study, establishing a new treatment option for this genetically defined patient population. In contrast, <strong>Bristol Myers Squibb&#8217;s adagrasib <\/strong>(KRAZATI) encountered a significant setback in 2026 after the confirmatory Phase III KRYSTAL-10 trial evaluating adagrasib plus cetuximab failed to meet its primary endpoint, creating uncertainty around its accelerated approval in metastatic CRC. Despite this setback, BMS continues to prioritize lung cancer through the ongoing Phase III KRYSTAL-4 and KRYSTAL-7 studies, evaluating adagrasib in combination with pembrolizumab (KEYTRUDA) for first-line treatment of NSCLC.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-generation-kras-inhibitors-to-reshape-the-current-therapeutic-landscape\"><span class=\"ez-toc-section\" id=\"Next-generation_KRAS_Inhibitors_to_Reshape_the_Current_Therapeutic_Landscape\"><\/span><strong>Next-generation KRAS Inhibitors to Reshape the Current Therapeutic Landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The KRAS inhibitor field has entered a second phase of evolution, shifting from proof-of-concept with first-generation KRAS G12C inhibitors toward next-generation therapies designed to improve efficacy, overcome resistance, expand into earlier treatment settings, and target a broader range of KRAS mutations.<\/p>\n\n\n\n<p>The most significant advancement in 2026 came from <strong>Roche&#8217;s next-generation KRAS G12C inhibitor divarasib (GDC-6036)<\/strong>. In the pivotal Phase III KRAScendo-1 trial, evaluating the drug in 338 patients with previously treated KRAS G12C-mutated advanced or metastatic NSCLC, divarasib demonstrated clinically meaningful and statistically significant improvements in both progression-free survival (PFS) and overall survival compared with the first-generation KRAS inhibitors sotorasib and adagrasib. The study also reported no new safety signals, with treatment-related adverse events remaining manageable and reversible. These results position divarasib as a potential new standard of care for previously treated KRAS G12C-mutated NSCLC and establish Roche as a leading competitor in the next generation of KRAS-targeted therapies.<\/p>\n\n\n\n<p>Moreover, Roche is further expanding divarasib into earlier stages of disease through the ongoing Phase III KRAScendo-2 trial, evaluating a chemotherapy-free combination of divarasib and pembrolizumab versus standard chemo-immunotherapy in first-line KRAS G12C-mutated NSCLC, and KRAScendo-3, assessing adjuvant divarasib following surgery and standard chemo-immunotherapy in patients with resected stage II-IIIB disease.<\/p>\n\n\n\n<p>Beyond divarasib, the development pipeline remains highly competitive. <strong>Eli Lilly&#8217;s olomorasib (LY3537982)<\/strong> has emerged as one of the leading next-generation KRAS G12C inhibitors and has received <strong>US FDA Breakthrough Therapy designation (BTD)<\/strong>. The drug is being evaluated in multiple pivotal studies, including in combination with pembrolizumab with or without chemotherapy for first-line advanced NSCLC, in combination with immunotherapy for resectable and unresectable NSCLC, and as both monotherapy and combination therapy across a range of advanced solid tumors. Recent clinical data presented at <a href=\"https:\/\/www.delveinsight.com\/asco-conference-2026\/all\">ASCO 2026<\/a> demonstrated encouraging efficacy, with objective response rates (ORRs) ranging from 55.6% to 76.9% and disease control rates (DCRs) of 87.0%\u2013100% across first-line NSCLC cohorts, while maintaining a manageable safety profile.&nbsp;<\/p>\n\n\n\n<p>Also advancing rapidly is <strong>Merck&#8217;s calderasib<\/strong>, which is in late-stage development for both NSCLC and CRC. Calderasib monotherapy demonstrated an<strong> ORR <\/strong>of<strong> 27% <\/strong>and a<strong> DCR<\/strong> of<strong> 71% <\/strong>in previously treated NSCLC, while its combination with pembrolizumab markedly improved efficacy, achieving an ORR of 72% and a DCR of 95%, with ORRs reaching 87%<strong> <\/strong>in patients with PD-L1 tumor proportion scores (TPS) \u226550%.&nbsp;<\/p>\n\n\n\n<p><strong>Jacobio&#8217;s glecirasib<\/strong> is advancing through multiple mid- to late-stage<strong> <\/strong>clinical trials in China for KRAS G12C-mutated NSCLC, CRC, and other advanced solid tumors, while <strong>InventisBio&#8217;s garsorasib (D-1553)<\/strong> is also progressing through late-stage clinical development in China across NSCLC and other KRAS G12C-positive malignancies.&nbsp;<\/p>\n\n\n\n<p><strong>D3 Bio&#8217;s elisrasib (D3S-001),<\/strong> which recently received <strong>FDA BTD<\/strong>, is another promising next-generation KRAS G12C inhibitor with an expanding Phase II program spanning second-line NSCLC, metastatic CRC, pancreatic cancer, first-line NSCLC in combination with immune checkpoint inhibitors, and CRC in combination with cetuximab. In an ongoing Phase I\/II study, first-line elisrasib monotherapy achieved an ORR of 78.0% and a DCR of 95.1%, with a median PFS of 12.4 months and a favorable safety profile. When combined with pembrolizumab, efficacy improved further, delivering an ORR of 81.3% and a DCR of 97.9%, while median PFS and OS were not yet reached, highlighting its potential as a competitive first-line treatment option for KRAS G12C-mutated NSCLC.&nbsp;<\/p>\n\n\n\n<p>While the G12C variant remains the most clinically advanced target, the next wave of innovation is rapidly expanding towards KRAS G12D, G12V, G12R, and pan-KRAS inhibitors, which have the potential to treat substantially larger patient populations across pancreatic, colorectal, and lung cancers. <strong>Revolution Medicines <\/strong>has emerged as a leader in this space with one of the industry&#8217;s most comprehensive RAS-targeted pipelines. Its multi-selective RAS(ON) inhibitor, <strong>daraxonrasib (RMC-6236)<\/strong>, is the most advanced non-G12C candidate, progressing through registrational studies in metastatic and adjuvant pancreatic ductal adenocarcinoma (PDAC), while also being evaluated in metastatic NSCLC and combination regimens for advanced solid tumors.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"436\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Competitive-Landscape-of-KRAS-mutated-NSCLC-1024x436.webp\" alt=\"Competitive-Landscape-of-KRAS-mutated-NSCLC\" class=\"wp-image-35885\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Competitive-Landscape-of-KRAS-mutated-NSCLC-1024x436.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Competitive-Landscape-of-KRAS-mutated-NSCLC-300x128.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Competitive-Landscape-of-KRAS-mutated-NSCLC-150x64.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Competitive-Landscape-of-KRAS-mutated-NSCLC-768x327.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Competitive-Landscape-of-KRAS-mutated-NSCLC-1536x654.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Competitive-Landscape-of-KRAS-mutated-NSCLC.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Complementing this program, the KRAS G12D-selective inhibitor <strong>zoldonrasib (RMC-9805)<\/strong> is advancing in first-line metastatic PDAC and NSCLC, with Phase III initiation planned in PDAC. Revolution Medicines is further broadening its portfolio with <strong>elironrasib (RMC-6291)<\/strong> targeting KRAS G12C and <strong>RMC-5127 <\/strong>targeting KRAS G12V, reinforcing the industry&#8217;s shift toward mutation-specific and pan-RAS therapeutic strategies that extend well beyond the first generation of KRAS G12C inhibitors. Additionally, Eli Lilly&#8217;s <strong>LY3962673<\/strong>, a selective KRAS G12D inhibitor, is in early clinical development for KRAS G12D-mutant solid tumors, further reinforcing the industry&#8217;s shift beyond KRAS G12C toward broader mutation-specific therapies.<\/p>\n\n\n\n<p>Beyond mutation-specific inhibitors, <strong>Cardiff Oncology&#8217;s onvansertib <\/strong>offers a mutation-agnostic strategy for KRAS-mutant mCRC. As a<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/plk1-inhibitor-market-forecast\"><strong>first-in-class PLK1 inhibitor<\/strong><\/a>, it targets downstream RAS signaling and is being evaluated in combination with standard-of-care chemotherapy and bevacizumab, with the potential to benefit a broader KRAS-mutant patient population beyond the relatively small KRAS G12C subset.&nbsp;<\/p>\n\n\n\n<p>In parallel, combination strategies utilizing <strong>EGFR<\/strong>, <strong>SHP2<\/strong>, <strong>SOS1<\/strong>, and <strong>MEK inhibitors<\/strong>, alongside <strong>immune checkpoint inhibitors,<\/strong> have become central to clinical development. These multidimensional approaches aim to block intrinsic and acquired compensatory signaling networks, delay resistance to KRAS monotherapies, and improve the durability of responses across multiple solid tumors&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pipeline-setbacks-reshaping-the-kras-therapeutic-landscape-nbsp\"><span class=\"ez-toc-section\" id=\"Pipeline_Setbacks_Reshaping_the_KRAS_Therapeutic_Landscape\"><\/span><strong>Pipeline Setbacks Reshaping the KRAS Therapeutic Landscape&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>While the KRAS therapeutic landscape continues to expand with next-generation and mutation-specific inhibitors, recent pipeline discontinuations indicate the scientific and commercial challenges of developing <a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-inhibitors-market\">KRAS-targeted therapies<\/a>. As the field becomes increasingly competitive, companies are prioritizing differentiated assets with the greatest potential to demonstrate meaningful clinical benefit over first-generation KRAS inhibitors.&nbsp;<\/p>\n\n\n\n<p>One of the most notable setbacks came in March 2025, when <strong>Bristol Myers Squibb<\/strong> discontinued development of <strong>MRTX1133<\/strong>, the selective KRAS G12D inhibitor acquired through its <strong>USD 4.8 billion acquisition of Mirati Therapeutics<\/strong>. MRTX1133 had been widely regarded as one of the leading KRAS G12D candidates, particularly for pancreatic and colorectal cancers, but its Phase I\/II study was terminated following completion of Phase I. According to the company, the decision was not driven by safety concerns but reflected an unfavorable pharmacokinetic profile that was considered highly variable and suboptimal.<\/p>\n\n\n\n<p>Similarly, <strong>Novartis<\/strong> discontinued development of its investigational <strong>KRAS G12C inhibitor<\/strong>,<strong> opnurasib (JDQ443)<\/strong>, following a strategic portfolio review. The decision resulted in the termination of all ongoing studies, including the pivotal Phase III KontRASt-02 trial in previously treated KRAS G12C-mutated NSCLC and the STRIDER study evaluating intracranial activity in patients with brain metastases. Importantly, Novartis stated that the decision was not related to efficacy or safety concerns, but rather reflected the increasingly crowded KRAS G12C landscape, where established therapies such as <strong>sotorasib<\/strong> and <strong>adagrasib<\/strong>, together with next-generation candidates including <strong>divarasib<\/strong>, <strong>olomorasib<\/strong>, <strong>calderasib<\/strong>, and <strong>elisrasib<\/strong>, have substantially intensified competition. Earlier Phase Ib\/II KontRASt-01 results had demonstrated encouraging activity, with an objective response rate of 57% and a favorable safety profile, indicating that commercial positioning, rather than clinical performance, ultimately drove the program&#8217;s discontinuation.<\/p>\n\n\n\n<p>These discontinuations highlight the changing dynamics of KRAS drug development, where success increasingly depends not only on demonstrating clinical efficacy but also on offering clear differentiation through superior efficacy, improved CNS activity, enhanced durability of response, broader mutation coverage, or more effective combination strategies. As a result, the industry&#8217;s focus is steadily shifting toward next-generation KRAS inhibitors and mutation-specific or pan-KRAS approaches capable of addressing larger patient populations and overcoming resistance mechanisms.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-outlook-of-the-kras-inhibitors-market-nbsp\"><span class=\"ez-toc-section\" id=\"Future_Outlook_of_the_KRAS_Inhibitors_Market\"><\/span><strong>Future Outlook of the KRAS Inhibitors Market&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The treatment landscape for KRAS-mutant cancers has rapidly evolved, with several promising advancements in recent years. The KRAS inhibitor market is expected to grow significantly over the coming years, driven by the increasing incidence of cancer and growing demand for precision oncology. Continued research and late-stage clinical development have broadened the therapeutic landscape beyond first-generation KRAS G12C inhibitors to include next-generation mutation-specific and pan-KRAS approaches.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s analysis, the market size for KRAS inhibitors reached over <strong>USD 500<\/strong> million in 2025 across the 7MM and is expected to witness robust growth through the forecast period, supported by increasing adoption of approved therapies and the anticipated launch of multiple late-stage pipeline candidates. As per the estimates, the US is expected to remain the largest market, accounting for the majority of market share across the seven major markets, driven by early adoption of targeted therapies, favorable reimbursement, and a high prevalence of KRAS-mutated cancers.<\/p>\n\n\n\n<p>NSCLC is anticipated to remain the largest market for KRAS-targeted therapies, supported by the continued uptake of <strong>sotorasib (LUMAKRAS)<\/strong> and <strong>adagrasib (KRAZATI)<\/strong> and the emergence of next-generation KRAS G12C inhibitors such as <strong>divarasib<\/strong>,<strong> olomorasib<\/strong>,<strong> calderasib<\/strong>,<strong> elisrasib<\/strong>, <strong>glecirasib<\/strong>, and<strong> garsorasib<\/strong>, which are expected to further reshape the competitive landscape. The focus is also expanding beyond KRAS G12C toward KRAS G12D, G12V, G12R, and pan-KRAS inhibitors, broadening the addressable patient population across multiple tumor types.<\/p>\n\n\n\n<p>Following NSCLC, <a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-market\">colorectal cancer<\/a> continues to demonstrate strong pipeline activity, with companies including <strong>Roche, Eli Lilly, Merck, Jacobio, InventisBio, D3 Bio, and Revolution Medicines<\/strong> advancing both mutation-specific and combination-based KRAS-targeted therapies. In parallel, <strong>Cardiff Oncology&#8217;s onvansertib<\/strong> continues to be evaluated as a mutation-agnostic approach for KRAS-mutant colorectal cancer. Although pancreatic cancer carries one of the highest frequencies of KRAS mutations, the treatment landscape remains comparatively less mature. However, increasing investment in KRAS G12D-targeted therapies and pan-KRAS inhibitors, particularly by <strong>Revolution Medicines<\/strong> and <strong>Eli Lilly<\/strong>, is expected to accelerate innovation and expand therapeutic opportunities in pancreatic cancer over the coming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion-a-glimpse-into-the-future\"><span class=\"ez-toc-section\" id=\"Conclusion_A_Glimpse_into_the_Future\"><\/span><strong>Conclusion: A Glimpse into the Future<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The KRAS therapeutic landscape has entered a new era, evolving from the first successful KRAS G12C inhibitors to a highly competitive pipeline of next-generation and mutation-specific therapies. Current innovation is focused on improving efficacy, overcoming resistance, and extending targeted treatment beyond G12C to address a broader spectrum of KRAS mutations.&nbsp;<\/p>\n\n\n\n<p>While the field continues to witness both significant clinical breakthroughs and strategic pipeline discontinuations, sustained investment and scientific innovation are expected to fuel its continued evolution. As more differentiated therapies and rational combination strategies move closer to clinical practice, KRAS-targeted treatments are poised to transform the management of KRAS-mutant cancers and further improve patient outcomes.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-inhibitors-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Market-Assessment-Analysis-1024x194.webp\" alt=\"KRAS Inhibitors Market Assessment Analysis\" class=\"wp-image-35883\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Market-Assessment-Analysis-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Market-Assessment-Analysis-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Market-Assessment-Analysis-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Market-Assessment-Analysis-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Market-Assessment-Analysis-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/KRAS-Inhibitors-Market-Assessment-Analysis.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-frequently-asked-questions\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1758864760462\"><strong class=\"schema-faq-question\"><strong>What are KRAS inhibitors beyond G12C, and why are they important in cancer treatment?<\/strong><\/strong> <p class=\"schema-faq-answer\">KRAS inhibitors beyond G12C are therapies designed to target other KRAS alterations, including G12D, G12V, G13D, and other rare mutations. They are important because KRAS mutations are among the most common drivers of cancer, and expanding inhibition beyond G12C could address a much larger patient population with limited targeted treatment options.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864773235\"><strong class=\"schema-faq-question\"><strong>Which KRAS mutations are being targeted in current clinical trials?<\/strong><\/strong> <p class=\"schema-faq-answer\">Current clinical trials are focusing on mutations such as KRAS G12D, G12V, G12R, G13D, and pan-KRAS alterations. Among these, G12D has gained significant attention due to its high prevalence in pancreatic, colorectal, and lung cancers, with multiple investigational inhibitors advancing through development.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864783924\"><strong class=\"schema-faq-question\"><strong>Why are combination therapies becoming essential for KRAS-mutant cancers?<\/strong><\/strong> <p class=\"schema-faq-answer\">Combination therapies are being explored to overcome resistance mechanisms and improve durability of response with KRAS inhibitors. Approaches combining KRAS inhibitors with agents targeting the MAPK pathway, immune checkpoints, SHP2, SOS1, or chemotherapy aim to enhance efficacy and prevent tumor adaptation.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864868322\"><strong class=\"schema-faq-question\"><strong>What are the biggest challenges in developing therapies for non-G12C KRAS mutations?<\/strong><\/strong> <p class=\"schema-faq-answer\">Major challenges include the structural complexity of KRAS mutations, difficulty achieving selective and potent inhibition, and the emergence of acquired resistance. Additionally, developing drugs that effectively target multiple KRAS variants while maintaining safety remains a significant hurdle.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758864879360\"><strong class=\"schema-faq-question\"><strong>How is the KRAS inhibitors market expected to evolve over the next decade?<\/strong><\/strong> <p class=\"schema-faq-answer\">The KRAS inhibitors market is expected to expand significantly as next-generation inhibitors targeting mutations beyond G12C enter clinical development and potentially gain approvals. Growth will be driven by broader patient eligibility, combination treatment strategies, biomarker-driven approaches, and increasing adoption of precision oncology.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>The KRAS G12C mutation obstructs the binding of GAP to KRAS, preventing GTP hydrolysis and keeping G12C-mutant KRAS continuously active. This sustained activation triggers the MAPK and PI3K signaling pathways, fueling the formation of tumors. Drugs like sotorasib and adagrasib directly target KRAS G12C by forming a bond with cysteine 12 in the KRAS-G12C protein\u2019s [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":26621,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1837,906,21634,17026,21632,21633,19862,21631,21635,19013,21630,1111,19011],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-26620","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-artificial-intelligence","tag-cancer-therapies","tag-colorectal-cancer-treatment","tag-kras-inhibitors","tag-kras-inhibitors-market","tag-kras-inhibitors-market-size","tag-kras-mutated-cancers","tag-krasg12c-mutations","tag-krazati","tag-lumakras","tag-metastatic-colorectal-cancer-treatment","tag-nsclc","tag-nsclc-treatment","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>The Future of KRAS Targeting Cancer Therapies Beyond G12C<\/title>\n<meta name=\"description\" content=\"Emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Future of KRAS Targeting Cancer Therapies Beyond G12C\" \/>\n<meta property=\"og:description\" content=\"Emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T10:31:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-29T12:38:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Future of KRAS Targeting Cancer Therapies Beyond G12C","description":"Emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c","og_locale":"en_US","og_type":"article","og_title":"The Future of KRAS Targeting Cancer Therapies Beyond G12C","og_description":"Emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers.","og_url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-07-29T10:31:52+00:00","article_modified_time":"2026-07-29T12:38:32+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C","datePublished":"2026-07-29T10:31:52+00:00","dateModified":"2026-07-29T12:38:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c"},"wordCount":2870,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png","keywords":["artificial intelligence","Cancer therapies","colorectal cancer treatment","KRAS Inhibitors","KRAS inhibitors market","KRAS inhibitors market size","KRAS-mutated cancers","KRASG12C mutations","KRAZATI","Lumakras","metastatic colorectal cancer treatment","NSCLC","NSCLC treatment"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c","url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c","name":"The Future of KRAS Targeting Cancer Therapies Beyond G12C","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png","datePublished":"2026-07-29T10:31:52+00:00","dateModified":"2026-07-29T12:38:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Emergence of KRAS inhibitors marks a pivotal moment in cancer therapeutics, offering a ray of hope for patients battling KRAS-mutant cancers.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864760462"},{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864773235"},{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864783924"},{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864868322"},{"@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864879360"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c.png","width":1200,"height":800,"caption":"kras-inhibitors-beyond-g12c"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864760462","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864760462","name":"What are KRAS inhibitors beyond G12C, and why are they important in cancer treatment?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"KRAS inhibitors beyond G12C are therapies designed to target other KRAS alterations, including G12D, G12V, G13D, and other rare mutations. They are important because KRAS mutations are among the most common drivers of cancer, and expanding inhibition beyond G12C could address a much larger patient population with limited targeted treatment options.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864773235","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864773235","name":"Which KRAS mutations are being targeted in current clinical trials?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Current clinical trials are focusing on mutations such as KRAS G12D, G12V, G12R, G13D, and pan-KRAS alterations. Among these, G12D has gained significant attention due to its high prevalence in pancreatic, colorectal, and lung cancers, with multiple investigational inhibitors advancing through development.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864783924","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864783924","name":"Why are combination therapies becoming essential for KRAS-mutant cancers?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Combination therapies are being explored to overcome resistance mechanisms and improve durability of response with KRAS inhibitors. Approaches combining KRAS inhibitors with agents targeting the MAPK pathway, immune checkpoints, SHP2, SOS1, or chemotherapy aim to enhance efficacy and prevent tumor adaptation.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864868322","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864868322","name":"What are the biggest challenges in developing therapies for non-G12C KRAS mutations?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Major challenges include the structural complexity of KRAS mutations, difficulty achieving selective and potent inhibition, and the emergence of acquired resistance. Additionally, developing drugs that effectively target multiple KRAS variants while maintaining safety remains a significant hurdle.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864879360","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c#faq-question-1758864879360","name":"How is the KRAS inhibitors market expected to evolve over the next decade?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The KRAS inhibitors market is expected to expand significantly as next-generation inhibitors targeting mutations beyond G12C enter clinical development and potentially gain approvals. Growth will be driven by broader patient eligibility, combination treatment strategies, biomarker-driven approaches, and increasing adoption of precision oncology.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/01\/08142906\/kras-inhibitors-beyond-g12c-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">artificial intelligence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">colorectal cancer treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAS Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAS inhibitors market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAS inhibitors market size<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAS-mutated cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRASG12C mutations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAZATI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lumakras<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">metastatic colorectal cancer treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NSCLC treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">artificial intelligence<\/span>","<span class=\"advgb-post-tax-term\">Cancer therapies<\/span>","<span class=\"advgb-post-tax-term\">colorectal cancer treatment<\/span>","<span class=\"advgb-post-tax-term\">KRAS Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">KRAS inhibitors market<\/span>","<span class=\"advgb-post-tax-term\">KRAS inhibitors market size<\/span>","<span class=\"advgb-post-tax-term\">KRAS-mutated cancers<\/span>","<span class=\"advgb-post-tax-term\">KRASG12C mutations<\/span>","<span class=\"advgb-post-tax-term\">KRAZATI<\/span>","<span class=\"advgb-post-tax-term\">Lumakras<\/span>","<span class=\"advgb-post-tax-term\">metastatic colorectal cancer treatment<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">NSCLC treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 weeks ago","modified":"Updated 2 weeks ago"},"absolute_dates":{"created":"Posted on Jul 29, 2026","modified":"Updated on Jul 29, 2026"},"absolute_dates_time":{"created":"Posted on Jul 29, 2026 4:01 pm","modified":"Updated on Jul 29, 2026 6:08 pm"},"featured_img_caption":"kras-inhibitors-beyond-g12c","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=26620"}],"version-history":[{"count":8,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26620\/revisions"}],"predecessor-version":[{"id":35886,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26620\/revisions\/35886"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26621"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=26620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=26620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=26620"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=26620"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=26620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}